When Treatment to #Autoimmune Diseases Fail, Combining Targeted Therapies Offers a Solution. NOW OUT @CellRepMed! 👀 We introduced Mitigation of Non-Response Signature (MNRS), a framework that uses longitudinal blood transcriptomic data across 6 IMIDs to systematically rank complementary (and incompatible) drug pairs. Targeted therapies reshaped how we treat immune-mediated inflammatory diseases (IMIDs), but primary non-response remains a major therapeutic ceiling. Combining treatments is a potential solution, yet prioritizing which drug pairs to test in clinical trials out of thousands of combinations is a massive hurdle. Key Findings: - Data-Driven Prioritization: MNRS successfully maps complementary pairs of biologics and small molecules using longitudinal patient data. - A Winning Pair in RA: In rheumatoid arthritis, combining anti-TNF and anti-IL-6R therapies emerged as highly complementary. - Mechanism Discovered: Single-cell analysis localized this drug complementarity specifically to CD14+ monocytes. - In Vivo Validation: In a collagen-induced arthritis mouse model, the anti-TNF + anti-IL-6R combination significantly outperformed monotherapy. Huge thanks to the entire team DOCTIS Project who made this work possible! @cnag_eu Centro Nacional de Análisis Genómico (CNAG) @OmniscopeAI @DoctisEU 🔗 Read the full open-access paper here: cell.com/cell-reports-medici…